Medicine for treating lipopolysaccharide/D-aminogalactose induced liver injury

The invention discloses a medicine for treating lipopolysaccharide/D-aminogalactose (LPS/GalN) induced liver injury. The medicine for treating lipopolysaccharide/D-aminogalactose (LPS/GalN) induced liver injury is forsythiaside A. The forsythiaside A is capable of alleviating liver pathological injury induced by lipopolysaccharide/D-aminogalactose (LPS/GalN), reducing content of malonaldehyde (MDA) and serum ALT (Alanine Aminotransferase) and AST (Aspartate Amino Transferase) levels. In addition, the forsythiaside A is capable of inhibiting NF-chiB activation, serum TNF-alpha and liver TNF-alpha levels caused by LPS/GalN. In addition, the forsythiaside A is capable of increasing expression of Nrf2 and haem oxygenase 1. Results show that the protection function of the forsythiaside A on LPS/GalN induced liver injury is achieved by activating Nrf2 and inhibiting NF-chiB activation. 本发明公开了种治疗脂多糖/D-氨基半乳糖胺(LPS/GalN)诱导肝损伤的药物，所述治疗脂多糖/D-氨基半乳糖胺(LPS/GalN)诱导肝损伤的药物为连翘酯苷A。本发明的连翘酯苷A可以减轻脂多糖/D-氨基半乳糖胺(LPS/GalN)诱导的肝脏病理损伤、丙二醛(M